0
Research
Comparison of Costs of Community and Mail Service Pharmacy
Norman V. Carroll, PhD; Va. Ilia Brusilovsky, BA; Va. Bryan York, BS; Robert Oscar, BPharm
J Am Pharm Assoc (2003) 2005;45:336-343. doi:10.1331/1544345054003796

Abstract

Objective  To compare the costs of prescriptions dispensed through mail service and community pharmacies to quantify the comparative costs of the two types of pharmacies.

Design  Modeling study based on 1-year of claims data from a cohort of patients.

Setting  A health plan in the northeastern United States.

Patients  Approximately 100,000 members of the health plan.

Intervention  The plan used a small pharmacy benefits manager (PBM) and a mail service pharmacy that was not owned by a major PBM, a three-tier benefit design, and specified that patients could get a 90-day supply through mail service for the equivalent of two 30-day community pharmacy copayments.

Main Outcome Measures  Actual total, ingredient, plan, and patient costs of prescriptions dispensed through a mail service pharmacy and the estimated costs of those same prescriptions at community pharmacies.

Results  Total costs for the 44,847 prescriptions dispensed through mail service were $6,401,624. Had these prescriptions been dispensed at community pharmacies, costs would have been $6,902,252. Ingredient costs were $6,401,624 through mail versus $6,633,170 at community pharmacies. Total costs to the health plan were $4,726,637 through mail versus $4,417,733 at community pharmacies. Member costs were $1,674,987 through mail versus $2,484,519 at community pharmacies.

Conclusion  Compared with community pharmacies, the mail service pharmacy was less expensive overall, less expensive for patients, but more expensive to the health plan. From the health plan's perspective, the loss of copayments in the mail service benefit was greater than the savings on ingredient costs and dispensing fees.

Sign In
APhA Members 
Welcome to JAPhA.org! Please log in below using your APhA username and password. Update your APhA profile.
Not a Subscriber
New to JAPhA? Become an APhA member to receive a full subscription to both the print and online editions.

OR

Register for a FREE limited account to benefit from personalization features such as alerts.

References

 National health expenditures—aggregate amounts and average annual percent change, by type of expenditure: selected calendar years 1980–2001. Accessed at cms.hhs.gov/statistics/nhe/historical/t2.asp, October 23,  2003.
 
Levit KR, Smith C, Cowan C, et al. Trends in U.S. health care spending, 2001.  Health Aff.  2003;22:154–64.[CrossRef]
 
 IMS Health Inc. DDD annual class-of-trade analysis 2002.  Plymouth Meeting, Pa.:  IMS Health Inc.;  2003.
 
 IMS America. Class of trade analysis: a pharmaceutical market overview using IMS/DDD data.  Totowa, N.J.:  IMS America;  1992.
 
Horgan C, Goody B, Knapp D, et al. The role of mail service pharmacies.  Health Aff.  1990;9:66–74.
 
 Pharmaceutical Care Management Association Web site. The value of mail service. Accessed at www.pcmanet.org, April 17,  2002.
 
Codling M. Rapid growth for mail-order drug dispensing.  Cambridge, Mass.:  Arthur D. Little Decision Resources;  1987.
 
Konnor DD.  The mail service pharmacy industry: growing by meeting the needs of managed health care.  J Res Pharm Econ.  1990;2:3–14.
 
Enright SM.  Mail-order pharmaceuticals.  Am J Hosp Pharm.  1987;44:1870–3.[PubMed]
 
 Sieben and Associates. Actuarial studies and reviews of mail order drug option experience.  Scottsdale, Az.:  PCS, Inc.;  1987.
 
 Pharmacy Benefit Management Institute. The Takeda prescription drug benefit cost and plan design survey report: 2002 edition.  Scottsdale, Ariz.:  Pharmacy Benefit Management Institute, Inc.;  2002.
 
Birtcher KK, Shepherd MD.  Users' perceptions of mail-service pharmacy.  Am Pharm.  1992;NS32:967–72.
 
Fried L. Rite Aid levels ‘paying’ field between drug-store and mail-order prescriptions.  Drug Store News.  1998;20(8):CP4.
 
 Patients prefer independents to mail order.  Drug Topics. 1999;143(5):10.
 
 PBM “self-dealing” could cost Medicare $30 billion.  America's Pharm. 2003;125(10):12.
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Please read the other comments before you post yours. Comments are moderated and will appear on the site at the discertion of the editorial staff.
* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content

Customize your page view by dragging & repositioning the boxes below.

JAPhA Articles
Topic Collections
PubMed Articles
Advertisement
 
  • Print
  • PDF Download
  • Email
  • Share
  • Get Citation
  • Submit Comment
  • Article Alerts
    Please Wait... Processing your request... Please Wait.
    You must sign in to sign-up for alerts.

    Please confirm that your email address is correct, so you can successfully receive this alert.

  • Letters To Editor
  • Reprints